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Abstract
Background: Individuals with a unilateral severe-to-profound hearing loss, or single-sided deafness, report difficulty
with listening in many everyday situations despite having access to well-preserved acoustic hearing in one ear. The
standard of care for single-sided deafness available on the UK National Health Service is a contra-lateral routing of
signals hearing aid which transfers sounds from the impaired ear to the non-impaired ear. This hearing aid has been
found to improve speech understanding in noise when the signal-to-noise ratio is more favourable at the impaired
ear than the non-impaired ear. However, the indiscriminate routing of signals to a single ear can have detrimental
effects when interfering sounds are located on the side of the impaired ear. Recent published evidence has suggested
that cochlear implantation in individuals with a single-sided deafness can restore access to the binaural cues which
underpin the ability to localise sounds and segregate speech from other interfering sounds.
Methods/Design: The current trial was designed to assess the efficacy of cochlear implantation compared to a
contra-lateral routing of signals hearing aid in restoring binaural hearing in adults with acquired single-sided deafness.
Patients are assessed at baseline and after receiving a contra-lateral routing of signals hearing aid. A cochlear implant
is then provided to those patients who do not receive sufficient benefit from the hearing aid. This within-subject
longitudinal design reflects the expected care pathway should cochlear implantation be provided for single-sided
deafness on the UK National Health Service. The primary endpoints are measures of binaural hearing at baseline, after
provision of a contra-lateral routing of signals hearing aid, and after cochlear implantation. Binaural hearing is assessed
in terms of the accuracy with which sounds are localised and speech is perceived in background noise. The trial is also
designed to measure the impact of the interventions on hearing- and health-related quality of life.
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Discussion: This multi-centre trial was designed to provide evidence for the efficacy of cochlear implantation compared to the
contra-lateral routing of signals. A purpose-built sound presentation system and established measurement techniques will provide
reliable and precise measures of binaural hearing.
Trial registration: Current Controlled Trials http://www.controlled-trials.com/ISRCTN33301739 (05/JUL/2013)
Keywords: Cochlear implantation, Single-sided deafness, Unilateral hearing loss, Contra-lateral routing of signals, Hearing aid,
Binaural hearing, Spatial listening
Background
Permanent acquired unilateral severe-to-profound hear-
ing loss, or single-sided deafness (SSD), has been esti-
mated to affect between 12–27 individuals in every
100,000 of the general population with the majority of
losses being sudden and idiopathic; that is, a cause has
not or cannot be determined [1]. Other aetiologies which
may give rise to SSD include Vestibular Schwannoma
(and associated surgery) and Ménière’s disease. Despite
having normal or near-normal hearing in one ear, indi-
viduals with SSD report difficulty when listening in many
everyday situations [2,3]. In particular, patients report dis-
ability when localising sounds and listening to sounds
on the side of the impaired ear [4]. Compatible with
these self-reported difficulties, individuals with SSD show
little or no ability to localise sounds [5-8] and dis-
play a poor ability to understand speech in noise when
the speech is on the impaired side of the head [5,6].
Both impairments reflect a lack of access to binaural
cues such as inter-aural time and level differences, while
the latter impairment also reflects the acoustic shadow
cast by the head which attenuates the high-frequency
components of sounds at the ear contra-lateral to their
source.
In the UK National Health Service (NHS), the stan-
dard of care for SSD is a Contra-lateral Routing of Signals
(CROS) hearing aid system. A CROS system picks up
sounds arriving at the impaired ear using a remote micro-
phone and presents those sounds to the non-impaired ear
through a wired or wireless link [9]. The primary function
of the system is therefore to overcome the acoustic shadow
cast by the head and, in doing so, to improve access to
sounds on the impaired side. The use of a CROS system
has been found to improve the perception of speech in
noise compared to the unaided condition when the most
favourable signal-to-noise ratio is available at the impaired
ear; i.e. with speech on the impaired side and the noise
from the front [6,10,11] or speech from the front and noise
on the non-impaired side [7,12,13]. Use of a CROS system
has also been associated with a reduction in self-reported
difficulty with background noise, communication, and
reverberation [1]. However, the indiscriminate routing
of sounds from the impaired ear to the non-impaired
ear can produce undesirable results. For example, the
perception of speech in noise can degrade with CROS use
compared to the unaided condition when a background
noise is located on the impaired side [6,11,13]. The use of
a CROS has also been found to have no effect on localisa-
tion accuracy [6,10,11] which is compatible with the fact
that the device is not designed to restore access to the
binaural cues which underpin the ability to locate sounds
in space. Finally, patients also report dissatisfaction with
the requirement to wear a hearing aid device on their
non-impaired ear [12,14].
Alternatives to a CROS include a Bone-Anchored Hear-
ing Device (BAHD) which also transmits sounds arriv-
ing on the impaired side to the non-impaired ear but
achieves this by conduction through the cranial bones.
There is some emerging evidence that BAHD may pro-
vide benefits to speech perception in noise over a CROS
system although more high quality trials are needed
[1,15]. BAHD is currently only commissioned in the
NHS in cases of profound unilateral sensorineural hear-
ing loss where conventional acoustic aiding (such as with
a CROS) is not possible or contra-indicated [16]. Like
the CROS, a BAHD does not restore binaural hearing in
individuals with SSD for whom the sensorineural com-
ponent of the hearing loss is severe-to-profound. Poor
localisation ability has been cited by patients as a fac-
tor which contributes to their decision not to receive a
BAHD, as have cosmetic concerns about the placement
of a permanent bone-anchored abutment through the
skin [17].
An alternative treatment for SSD which does have the
potential to restore access to binaural cues is cochlear
implantation. In cases of SSD where the auditory nerve
is intact, impairments of the middle and inner ear can be
bypassed and the auditory nerve stimulated electrically.
Like CROS and BAHD devices, cochlear implantation in
SSD has been found to improve access to sounds on the
impaired side and has been associated with a reduction
in self-reported difficulties with listening to speech in
noise [5,18,19].Unlike CROS and BAHDdevices, cochlear
implantation has also been found to improve the accu-
racy with which sounds can be localised [5,18,19]. Thus,
the restoration of input to the impaired ear has the capac-
ity to provide access to the inter-aural cues which sup-
port localisation and to restore useful aspects of binaural
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hearing. The intervention therefore has the potential to
alleviate the high-levels of difficulty that individuals with
SSD report with understanding speech in many every-
day situations containing background noise [4] and, in
doing so, may improve their health-related quality of
life [20].
In the NHS, cochlear implantation is currently commis-
sioned for adults and children with bilateral severe-to-
profound deafness [21] and is not commissioned routinely
for individuals with SSD. Providing a cochlear implant in
cases of SSD and supporting its effective use throughout
the lifespan is likely to incur a substantially greater cost to
the NHS compared to the provision and maintenance of
the current standard of care, a CROS system. A cochlear
implant is also a lifetime commitment and involves a sur-
gical procedure whereas a CROS system is no more per-
manent or invasive than a conventional acoustic hearing
aid. For these two reasons, it was anticipated that cochlear
implantation would be unlikely to be considered as an
alternative to CROS in the NHS. Rather, it may be con-
sidered as an intervention for SSD in cases where a CROS
system has been found to offer insufficient benefit as in
these cases no other treatment options are currently avail-
able on the NHS. The current trial was therefore designed
to evaluate whether cochlear implantation provides ben-
efit to those patients who report receiving insufficient
benefit from a CROS system.
Purpose
This within-subjects longitudinal trial will determine
whether cochlear implantation provides significant bene-
fit in patients who have failed to receive sufficient benefit
from a Contra-lateral Routing of Signals (CROS) system.
Primary objectives
• Does a cochlear implant significantly improve sound
localisation compared to a CROS hearing aid in
patients who report insufficient benefit from a CROS?
• Does a cochlear implant significantly improve speech
perception in noise compared to a CROS hearing aid
in patients who report insufficient benefit from a
CROS?
Secondary objective
• Does a cochlear implant significantly improve quality
of life compared to a CROS hearing aid in patients
who report insufficient benefit from a CROS?
Methods/Design
The trial is a within-subjects longitudinal study in which
participants will be assessed before and after receiving
two interventions delivered in a fixed order. Participants
will be recruited from five NHS Trusts in the UK: (1)
Nottingham University Hospitals NHS Trust; (2) Uni-
versity Hospitals Birmingham NHS Foundation Trust;
(3) Central Manchester University Hospitals NHS Foun-
dation Trust; (4) University College London Hospitals
NHS Foundation Trust; and (5) Guy’s and St. Thomas’
NHS Foundation Trust. The trial is being coordinated
by the National Institute for Health Research (NIHR)
Nottingham Hearing Biomedical Research Unit, Notting-
ham. After screening against the inclusion/exclusion cri-
teria, participants will progress through three phases:
baseline, CROS, and cochlear implantation (Figure 1).
During the two-month baseline phase, participants
receive no treatment; in the CROS phase, participants will
be fitted with a CROS system and complete a 3-month
Baseline CROS Cochlear Implantation
Screening interview
Questionnaires Device fitting
Listening
assessments
Questionnaires
Questionnaires
Questionnaires &
Listening assessments 
Surgery
Device fitting 
Questionnaires
3 months
6 months
1 month
2 months
2 months
Questionnaires &
Listening assessments 
User diary
User diary User diary
User diary
Figure 1 Trial design. A schematic representation of the sequence and timing of appointments that each participant will complete divided into
the three trial phases. In the baseline phase, participants will use no hearing-assistive device and the listening tests will be administered during the
two-month delay between baseline questionnaire assessments. After both CROS and cochlear implant fitting, participants will complete a daily
diary to track device usage and to capture any comments on the advantages/disadvantages of the devices. CROS: Contra-lateral Routing of Signals.
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trial of the device; in the cochlear implantation phase par-
ticipants will receive a cochlear implant and follow-up will
continue for 9 months.
The duration of the CROS trial (3 months) was cho-
sen in consultation with clinical colleagues from several
UK audiology services to ensure that (a) it was of suffi-
cient duration to allow the benefits fromCROS to emerge;
(b) any benefits from CROS would have stabilised; and
(c) self-reported benefits would be based on patients’
experience of CROS use rather than any pre-conceived
expectations (whether positive or negative). The duration
of the cochlear implantation follow-up period (9 months)
was chosen based on data from previous studies which
have observed that (a) a large proportion of the benefit
from cochlear implantation is achieved within the first 9
months and additional benefits emerge at a slower rate
over the course of several years [22,23]; and (b) significant
benefits to binaural hearing from cochlear implantation in
patients with SSD can be achieved as early as 6 months
after implantation [5].
The primary endpoints are the assessments of sound
localisation and speech understanding in noise at baseline,
after CROS aiding, and after cochlear implantation. Sec-
ondary endpoints are questionnaire measures of hearing-
and health-related quality of life and the impact of tin-
nitus at baseline, after CROS aiding, and after cochlear
implantation.
The trial protocol and the study activities across the
five NHS trusts were given a favourable opinion by
the National Research Ethics Committee, East Midlands
Nottingham - 2, Nottingham, UK (12/EM/0378). The
sponsor of the trial is Nottingham University Hospi-
tals NHS Trust, Research and Innovation Department,
Nottingham, UK.
Population and sample size
Participants will be recruited from a notes review at each
of the participating hospitals. The primary outcome mea-
sure is sound localisation accuracy; specifically, the mean
absolute angular error in localising speech sounds. The
trial is powered to detect a within-subject improvement
in mean localisation accuracy resulting from the use of a
cochlear implant compared to, and following the use of,
a Contra-lateral Routing of Signals (CROS) hearing aid.
A previous study examined the within-subject improve-
ment in localisation accuracy after cochlear implantation
compared to brief periods of CROS and simulated BAHD
use prior to implantation [5]. The authors reported local-
isation performance after 3-week trials of both a CROS
aid and a BAHD on a soft band (without a perma-
nent bone-anchored abutment), completed in a random
order. They subsequently reported localisation perfor-
mance data obtained 6 months after participants had
received a cochlear implant.
Arndt et al. [5] reported the median, range, and inter-
quartile range of localisation performance at the end of the
follow-up period for each device. Standard deviations for
the localisation performance data after 3 weeks of CROS
use and after 6 months of cochlear implant use were
estimated from the inter-quartile ranges [24]. As only
summary statistics were available, the correlation between
the CROS (i.e. pre-cochlear implant) and post-cochlear
implant measures could not be determined. The data were
assumed to be uncorrelated yielding an estimated effect
size of 1.63 standard deviations. To detect an effect of this
magnitude using a one-tailedWilcoxon signed-rank test at
α = 0.05 and with 95% power would require a sample size
of 7. A final sample size of 10 was chosen to achieve the
desired statistical power and to allow for some attrition
due to the length of the follow-up period after cochlear
implantation (9 months). The desired power reflects the
fact that a study of this nature is unlikely to be repeated
due to the substantial cost of providing the participants
with a cochlear implant.
Inclusion criteria
• Eighteen years of age or older at the time of entry to
the trial
• Able and willing to undertake all assessments
required by the trial
• Good understanding of written and spoken English
• Poorer ear (ear to be implanted):
– Acquired (post-lingual) severe-to-profound
sensorineural hearing loss of < 10 years
duration
– Severe-to-profound deafness defined as
having hearing threshold > 90 dB HL at 1 & 4
kHz, and > 65 dB at 0.5 kHz
– Minimal benefit from a hearing aid (see below)
• Better ear (contra-lateral ear): Normal or
near-normal hearing. For the purposes of this trial
this is defined as hearing thresholds with a pure-tone
average (PTA) of ≤ 30 dB HL at 0.5, 1, & 2 kHz.
The process that will be used to determine minimal
benefit from a hearing aid is illustrated in Figure 2. For
those patients who use a hearing aid at the time of the
screening interview, speech perception performance in
the best-aided condition will be assessed using a method
similar to that used for traditional cochlear implanta-
tion candidates [21]. Two lists of Bamford-Kowal-Bench
(BKB) sentences will be presented at 70 dB Sound Pres-
sure Level from a loudspeaker positioned in front of the
patient while their normal hearing ear is occluded using
a combination of an earplug and a circumaural muffler.
Performance will be measured in terms of the propor-
tion of keywords reported correctly. If less than 50% of
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Figure 2 Functional screening assessment. A flow chart of the screening process concerned with assessing potential participants against the
inclusion criterion governing the acceptable level of function in the impaired ear. If aidable, functional performance will be assessed while the NH
ear is occluded using an earplug and circumaural mufflers. Should the level of function still fall outside criterion, performance will be assessed again
but while a masking noise is also presented to the NH ear. Individuals who cannot be aided, either because it is deemed clinically inappropriate or
because it is not possible fit an aid (e.g. few or no measurable audiometric thresholds), will be eligible for inclusion. NH: Normal Hearing.
keywords are reported correctly, the patient will be con-
sidered as receiving minimal benefit from their hearing
aid. If the percentage of keywords reported correctly is
50% or greater, performance will be reassessed using two
different BKB lists while the function of the normal hear-
ing ear is further degraded using a combination of a
masking noise presented at 50 dB(A) via an insert tube-
phone and a circumaural muffler. If less than 50% of the
keywords are reported correctly withmasking, the patient
will be considered as receiving minimal benefit from their
hearing aid.
For those patients who do not use a hearing aid at the
time of the screening interview, an assessment will be
made as to whether it would be clinically appropriate to
provide amplification in the impaired ear. This assessment
process will reflect current standard clinical practice. If
the provision of a hearing aid would be clinically appro-
priate, the patient will be referred for hearing aid fitting to
confirm whether the level of gain being called for can be
obtained using any of the hearing aid models available on
the NHS, and whether the prescription can be achieved.
Verification of the prescription will be determined using
real-ear measurements [25]. If the necessary gain can be
provided and the prescription can be achieved, the patient
will undergo a trial of a hearing aid at their local audiology
centre before speech perception is assessed in their best-
aided condition as described above. The duration of the
trial will vary according to local practice but will last for a
minimum of four weeks. If amplification is deemed inap-
propriate, or the necessary gain cannot be provided or
achieved, the patient will be deemed to be unaidable and
will be considered for inclusion in the trial.
Participants may have previous experience with using
a CROS system. However, participants must have ceased
use of any CROS system prior to entry into the study so
that they may be evaluated in their unaided state during
the baseline phase.
Exclusion criteria
• Evidence of middle-ear pathology based on otologic
examination and tympanometry
• Medical or psychological conditions that
contraindicate undergoing surgery
• Tinnitus as primary motivation for treatment
• Ossification or any other cochlear anomaly that might
prevent complete insertion of the electrode array
• Hearing loss of neural or central origin, including
auditory neuropathy and neurofibromatosis type II
• Additional handicaps that would prevent or restrict
participation in the audiological evaluations
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• Unrealistic expectations on the part of the participant
regarding the possible benefits, risks, and limitations
which are inherent to the surgical procedure and
prosthetic device
• Unwillingness of the participant to comply with all of
the trial requirements
• Any known factor which would limit the benefit
obtainable from a cochlear implant
A participant will be withdrawn from the trial if there
is a failure of the cochlear implant device or they experi-
ence a serious or intolerable device-related adverse event
leading to the explant or discontinued use of the cochlear
implant device. Participants may withdraw themselves
from the trial at any time and without giving a reason.
Participants who withdraw voluntarily during the CROS
or cochlear implantation phases may continue to use their
current device (CROS or cochlear implant) indefinitely.
Interventions
Contra-lateral routing of signals
The CROS hearing aid comprises a conventional acoustic
hearing aid and a remote microphone. The remote micro-
phone is worn on the impaired ear and the hearing aid
is worn on the non-impaired ear. Sounds arriving at the
impaired ear are picked up by the remotemicrophone and
sent via a wireless link to the hearing aidwhich delivers the
sounds via air conduction to the non-impaired ear. The
acoustic coupling for the hearing aid is selected to have
the smallest possible impact on the sound arriving at the
non-impaired ear.
The trial will use the Phonak CROS system (Phonak AG,
Stäfa, Switzerland). The system will be fitted by an expe-
rienced audiologist using the standard fitting software
provided by Phonak (Target™3.0). The fitting procedure
ensures that the acoustic information at the non-impaired
ear is similar regardless of whether a sound source is inci-
dent to the impaired or non-impaired ear [26,27]. The fit
will be verified using real-ear measurements. At the time
of fitting, participants will be encouraged to use the CROS
system for as long as possible each day and to record the
number of hours of use in their user diary each day. Par-
ticipants will attend a follow-up appointment after one
month of CROS use during which their initial usage will
be assessed, additional encouragement will be given, and
the fitting adjusted as required.
Cochlear implant
A cochlear implant comprises an externally-worn sound
processor and a wholly-implantable receiver-stimulator.
The receiver-stimulator is connected to a micro-electrode
array that is surgically-inserted into the inner ear
(cochlea). Sounds are picked up by one or more micro-
phones in the sound processor and are separated into
frequency bands containing both slow changes in ampli-
tude over time (envelope) and rapid changes in frequency
around the centre frequency of each band (fine structure).
The sound processor extracts the envelope in each fre-
quency band and uses the envelopes to define the pattern
of pulses to be delivered by each electrode. The pulse pat-
terns are delivered through the scalp to the implanted
receiver-stimulator via a radio-frequency coil.
The trial will use the CochlearTM Nucleus Cochlear
Implant System (Cochlear Ltd, NSW, Australia). The
Nucleus CI442 implant will be implanted by experi-
enced ENT surgeons. The implant systemwill be activated
once the wound has healed, typically 3–6 weeks after
surgery, and the sound processor will be fitted by an expe-
rienced cochlear implant audiologist. The programme
of post-activation fitting and rehabilitation appointments
will reflect the current standard care delivered to tradi-
tional cochlear implant candidates in the UK. Participants
will be encouraged to use their cochlear implant for as
long as possible each day and to record their actual usage
in their user diary. Participants will also be encouraged
to follow a rehabilitation programme which will include
listening to speech materials fed directly into the sound
processor of the implant via an accessory cable.
Device fitting procedures
CROS
The CROS fitting procedure aims to preserve the res-
onance characteristics of the non-impaired ear and to
overcome the head shadow which would otherwise atten-
uate sounds arriving at the impaired ear. The procedure
requires the use of Real Ear Measurements (REMs). REMs
will be carried out according to recommendations from
the British Society of Audiology [25] and manufacturer-
specific instructions based on the fitting hardware and
software being used. This will include the choice of stim-
ulus type, equipment setup, fitting environment, partici-
pant positioning, and probe calibration method.
The probe tube will be calibrated prior to commenc-
ing the fitting procedure. The procedure involves making
three probe measurements [26]:
1. A real-ear unaided response (REUR) while the
loudspeaker is positioned 45 degrees towards the
non-impaired ear. The probe tube and reference
microphone are both situated at the non-impaired
ear. The CROS system is not worn during this
measurement.
2. A real-ear aided response (REAR 1) measured using
the same setup as for the REUR. The CROS system is
worn and turned on during this measurement.
3. A second real-ear aided response (REAR 2) measured
while the loudspeaker is positioned 45 degrees
towards the impaired ear. The probe tube is still
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situated at the non-impaired ear but the reference
microphone is situated at the impaired ear.
The measurement REAR 1 will be compared to the
REUR to confirm that the coupling of the hearing aid
to the non-impaired ear is largely acoustically transpar-
ent. Any gross dissimilarity will be addressed by checking
and reconsidering the method of acoustic coupling. The
REAR 1 and REAR 2 measurements will be compared and
checked to be within±3 dB across the available frequency
range. Any deviations between the twomeasurements will
be addressed by adjusting the gain of the CROS system
and repeating the measurement of REAR 2.
The available fitting hardware and software at each
of the five trial sites may not permit the separation of
probe tube and reference microphone on opposite sides
of the head as required for the measurement of REAR 2.
An alternative procedure has been described based on a
stored equalisation method [27] and will be used where
probe and reference cannot be separated.
Cochlear implant
The cochlear implant fitting procedure will follow the
manufacturer-recommended procedure for fitting using
the Custom Sound software. The default programming
parameters specified by the manufacturer will be used
unless the individual needs of a patient require a devi-
ation from those parameters to maximise benefit. In
general terms, the fitting procedure will involve check-
ing electrode impedances, disabling electrodes based on
impedance measurements and/or intra-operative find-
ings, creating a mapping between input frequency bands
and electrodes (MAP), and establishing the minimum
detectable (threshold) stimulation level and the maximum
comfortable stimulation level for each electrode.
Cochlear implant fitting is an iterative process to max-
imise hearing function, reflecting the emergence of hear-
ing function over time due to a gradual acclimatisation
and adaptation to electrically-delivered information. Par-
ticipants will therefore attend several programming ses-
sions in the initial months after activation of their implant
through which their MAP, threshold levels, and comfort
levels will be fine tuned to maximise speech understand-
ing and acceptability to the patient.
Primary outcomemeasures
Assessments of the ability to localise sounds and under-
stand speech in noise will be administered using a
purpose-built test setup [28-30] in an anechoic chamber
at the MRC Institute of Hearing Research in Nottingham.
Sound localisation
Sound localisation will be measured in anechoic con-
ditions and a range of reverberant conditions following
established methods using a visual-pointing technique
[31]. On each trial, a short pre-recorded speech seg-
ment will be presented from one of several loudspeakers
positioned in the frontal plane and behind an acoustically-
transparent curtain (Figure 3). Speech segments will be
short isophonemic words [32] spoken by a male talker
with a British accent. The task of participants will be to
indicate the perceived location of the sound by moving
a visual pointer projected onto the curtain. The position
of the visual pointer will be adjusted using a computer-
controlled trackball mouse and with a precision exceeding
one degree of visual angle. Presentation levels will be
roved from trial to trial to restrict the use of monau-
ral loudness cues and limited so that stimuli do not
engage the compression features of the cochlear implant
sound processor which can degrade inter-aural level cues
[33-35].
The original speech waveforms will be presented after
being convolved with the room impulse of a simulated
room, the methods and parameters of which have been
described previously [30]. The ratio between the direct
Figure 3 Testing apparatus. The apparatus that will be used to assess the sound localisation accuracy and speech understanding of patients in
the trial. An array of loudspeakers and a visual projection system are positioned within an anechoic chamber. Thirty-six loudspeakers are distributed
horizontally around the listening position with an additional 6 loudspeakers suspended above the listener and a further 6 loudspeakers positioned
below the listener. The three visual projection screens are driven by three high-definition projectors. Responses are recorded using a trackball
(localisation task) or through an intercom (speech understanding task).
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and reverberant sound will be varied to simulate differ-
ent room characteristics from anechoic (no reflections)
to highly-reverberant. Localisation accuracy in anechoic
conditions will reflect the ability of participants to access
and use monaural spectral cues and inter-aural cues under
ideal listening conditions. Comparison of localisation in
anechoic conditions and in reverberant conditions will
identify the level of reverberation that participants can
tolerate while maintaining accuracy. Summary measures
of localisation accuracy will be reported for each individ-
ual participant along with measures of bias and variance
in their responses. The trial is powered using localisa-
tion data from a previous before-after study of cochlear
implantation following CROS and simulated BAHD use [5].
Speech understanding in noise
Speech understanding in noise will be measured in terms
of a speech-reception threshold (SRT) which represents
the signal-to-noise ratio (SNR) at which 50% of sentences
are reported correctly. Sentences will be drawn from a
recording of the IEEE sentence corpus [36] spoken by a
female talker with a British accent. The masking noise will
be generated to match the long-term average spectrum
of the sentences. SRTs will be measured using an adap-
tive procedure to avoid floor and ceiling effects by varying
the level of the speech and noise from trial to trial based
on the accuracy with which the participant recalls key-
words in the sentences [37]. The spatial configuration of
the speech and the noise will be varied across testing con-
ditions to estimate the three main effects of two-eared
listening to speech in noise [38]: i) the head-shadow effect
estimated from the test conditions in which the speech is
positioned on the side of the impaired ear and the noise
is on the side of the non-impaired ear; ii) binaural squelch
effect estimated from the test conditions in which the
noise is positioned on the side of the impaired ear and
the speech is on the side of the non-impaired ear; iii) bin-
aural summation (redundancy) effect estimated from the
test conditions in which the speech and noise are posi-
tioned equidistant from both ears; i.e. directly in front of
the participant. SRTs will be reported for each individual
participant along with a measure of the variance of the
SNRs used to compute each SRT.
Secondary outcomemeasures
Hearing-specific quality of life questionnaires
The Speech, Spatial and Qualities of Hearing Scale (SSQ)
[39] contains 47 questions organised into three sections.
The Speech section asks about difficulties with under-
standing speech in a range of everyday situations. The
Spatial section asks about difficulties with localising
sound sources and tracking moving sounds. TheQualities
section asks about difficulties with the perceived natu-
ralness of sounds, separating sounds, and the amount of
effort required to listen. The SSQ has been found to be
capable of distinguishing between groups of unilateral and
bilateral hearing aid [40] and cochlear implant [41] users,
confirming its sensitivity to spatial hearing abilities, and
found to have a test-retest reliability of 0.83 [42].
Glasgow Hearing Aid Benefit Profile (GHABP) has
been developed as a patient-centred outcome measure
designed to measure the disability caused by a patient’s
hearing loss before and after hearing aid fitting and the
impact that the disability has on a patient’s everyday life
[43,44]. The GHABP asks six questions about four spe-
cific listening situations and up to four listening situations
nominated by the patient. Each question is a five-point
Likert scale. The six questions correspond to the six
domains of initial disability, impact on life (handicap),
device use, device benefit, residual disability, and device
satisfaction.
The Glasgow Benefit Inventory (GBI) is an instru-
ment for measuring changes in quality of life as a result
of otorhinolaryngological interventions [45]. The GBI is
designed to be administered after the intervention has
been received and provides a direct measure of its effect
on the health state of the patient. The 18 questions are
grouped to form three sub-scales: general, social sup-
port, and physical health. The GBI has been found to be
responsive to unilateral cochlear implantation [46].
Tinnitus Functional Index (TFI) has been designed
to measure treatment-related changes in tinnitus intru-
siveness and severity. The development of the TFI
has included the definition of the minimum clinically-
important change in TFI score (13 points) and identified a
test-retest reliability of 0.78 [47].
A user diary will also be provided in booklet form for
the 3-month trial of the CROS system and for the 9-month
follow-up period after cochlear implantation. Participants
will be instructed to record the duration of their device use
on a daily basis and will also be encouraged to record any
comments about situations in which either intervention
was particularly helpful or unhelpful.
Generic quality of life questionnaires
The Health Utilities Index Mark 3 (HUI3) is a generic
preference-based method for describing health status and
measuring health-related quality of life [48]. The HUI3
health status classification system describes an individ-
ual’s health state on eight dimensions of health: vision,
hearing, speech, ambulation, dexterity, emotion, cogni-
tion, and pain. The utility value for a chronic health state
described using the classification system can be calcu-
lated using the HUI3 multi-attribute utility function. The
multi-attribute function has been derived based on the
preferences of a sample of the Canadian general public
[49,50].Utility values are defined by a scale onwhich death
has a value of 0 and perfect or optimal health has a value
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of 1. Utility values derived using the HUI3 are suitable for
use as part of a health-economic analysis. The HUI3 has
been found to be responsive to interventions for hearing
loss including acoustic hearing aids [51,52] and cochlear
implants [53].
The EQ-5D is a generic method for describing and valu-
ing health states [54,55]. The EQ-5D has two components.
The first component is a system for describing a health
state on five dimensions of health: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression.
A single utility value or ‘tariff ’ for a health state can be cal-
culated using a model which describes the preferences of
a sample from the UK population [56]. The second com-
ponent is a visual-analogue scale (VAS) used to obtain
the patient’s own opinion of their current health state.
The EQ-5D has been found to be unresponsive to changes
in health-related quality of life arising from severe-to-
profound deafness [57] and provides smaller estimates
for the change in utility after cochlear implantation com-
pared to the HUI3 [46]. However, the EQ-5D is the pre-
ferred instrument of the UK National Institute for Health
and Care Excellence (NICE) for measuring health-related
quality of life [58].
Statistical methods, data analysis and reporting
Analysis of the trial data will include all patients who
pass the inclusion and exclusion criteria and will be con-
ducted on an intention-to-treat basis. Participants who
are withdrawn at any stage will be replaced. Participants
who choose to leave during the baseline or CROS phases
of the trial will be replaced. Participants who choose
to leave after receiving a cochlear implant will not be
replaced. Data from participants who choose to leave will
be retained and included in the analyses of individual
trial phases; i.e. baseline, CROS, and cochlear implan-
tation. Due to the small sample size, missing data will
not be imputed when conducting within-subject com-
parisons of the incremental change from baseline to
CROS and from CROS to cochlear implantation. Drop-
out rates at each phase of the trial will be reported
as a marker of potential bias in the between-phase
comparisons.
Baseline characteristics of the participants will be
reported including (but not limited to) age, gender, audio-
metric thresholds, aetiology and history of hearing loss,
duration of severe-to-profound deafness, and history of
hearing aid use.
Efficacy analysis
The primary endpoint and analysis of the trial data will be
at the end of the 9-month follow-up period after cochlear
implantation. The analysis will compare outcomes in the
cochlear implant phase to outcomes in the CROS phase.
Outcomes in the CROS and baseline phases will also be
compared. Comparisons will be performed for both the
primary and secondary outcome measures. Comparisons
both within and between trial phases will be performed
using paired Student’s t-tests,Wilcoxon signed-rank tests,
and repeated-measures analysis of variance, as appropri-
ate. For each outcome measure, summary measures of the
size and variance in the incremental benefit from cochlear
implantation (difference between cochlear implantation
and CROS) and CROS (difference between CROS and
baseline) will be reported.
Safety analysis
The reporting of adverse and serious adverse events will
follow the standard operating procedure (SOP) for trials
of medical devices specified by the sponsor organisation
(Nottingham University Hospitals NHS Trust SOP 52).
Discussion
Self-report and behavioural data confirm that individ-
uals with SSD experience difficulties with listening to
sounds on the side of their impaired ear and in deter-
mining the location of sounds in space [2-4]. Current
treatment options for SSD primarily aim to improve
access to sounds arriving at the impaired ear by utilis-
ing the intact hearing in the contra-lateral ear. Sounds
at the impaired ear are transmitted to the non-impaired
ear either via a wireless link and a conventional acoustic
coupling (CROS) or by conduction via the cranial bones
(BAHD). Individually, both systems have been found
to be efficacious compared to an unaided condition in
improving speech perception in noise but the systems do
not improve the ability to localise sounds [1]. Cochlear
implantation in SSD can restore the ability to localise
sounds [5,18,19] by providing access to the inter-aural
cues which underpin accurate localisation [35] and thus
has the potential to support useful aspects of binaural
hearing.
The current trial has been designed to provide evidence
for the efficacy of cochlear implantation as an intervention
in SSD compared to the current standard of care, a CROS
system. A cochlear implant will be offered to those who
receive insufficient benefit from a CROS system and for
whom few other treatment options currently exist on the
UK NHS. Participants will be evaluated prior to any inter-
vention (baseline), after 1 and 3 months of CROS use, and
at 3 and 9 months after cochlear implantation. The use
of established measurement techniques [31] and a sound
presentation system purpose-built for assessing speech
perception in noise and sound localisation accuracy [28]
will provide high-quality and reliable measures of binau-
ral hearing; all patients will be tested in the same centre
to reduce variability and improve trial consistency. The
use of generic- and hearing-related instruments to assess
health-related quality of life will provide estimates of the
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incremental change in quality of life after cochlear implan-
tation to inform future trials of the cost-effectiveness of
cochlear implantation in SSD.
Trial status
The trial is currently in recruitment phase.
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